Aptevo Therapeutics
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 40
- Market Cap
- -
- Introduction
Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded in February 2016 and is headquartered in Seattle, WA.
Clinical Trials
9
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Aptevo Therapeutics
- Target Recruit Count
- 39
- Registration Number
- NCT06634394
- Locations
- 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸University of Miami, Miami, Florida, United States
🇺🇸University of Kansas, Fairway, Kansas, United States
ALG.APV-527 First-in-human Study
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- Aptevo Therapeutics
- Target Recruit Count
- 56
- Registration Number
- NCT05934539
- Locations
- 🇺🇸
Hematology Oncology Associates Of The Treasure Coast, Port Saint Lucie, Florida, United States
Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML
- Conditions
- AML
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2021-12-01
- Lead Sponsor
- Aptevo Therapeutics
- Registration Number
- NCT04973618
Study to Evaluate APVO210 in Healthy Subjects, Patients With Psoriasis, and Patients With Ulcerative Colitis
- Conditions
- PsoriasisUlcerative Colitis
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2021-05-19
- Lead Sponsor
- Aptevo Therapeutics
- Target Recruit Count
- 85
- Registration Number
- NCT03768219
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
Study of ES414 in Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2014-10-13
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Aptevo Therapeutics
- Target Recruit Count
- 35
- Registration Number
- NCT02262910
- Locations
- 🇺🇸
University of California, San Francisco, California, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Central Texas Veterans Health Care System, Temple, Texas, United States
- Prev
- 1
- 2
- Next
News
Aptevo Advances APVO711: Novel Bispecific Antibody Combining PD-L1 Checkpoint Inhibition with CD40 Immune Activation
Aptevo Therapeutics has announced progress on APVO711, a dual-mechanism bispecific antibody that simultaneously blocks PD-L1 and activates CD40, potentially overcoming resistance to standard checkpoint inhibitors.
Aptevo Therapeutics Secures $2.1 Million in Financing to Advance Immune-Oncology Pipeline
Aptevo Therapeutics has closed a $2.1 million financing through a registered direct offering and concurrent private placement priced at $1.19 per share.
Aptevo's ALG.APV-527 Shows Promise in Solid Tumors with Favorable Safety Profile in Phase 1 Trial
Phase 1 dose escalation study of ALG.APV-527 demonstrates disease stabilization in 59% of evaluable patients across multiple solid tumor types, with notable durability in breast, colon, and prostate cancers.
Aptevo's Mipletamig Achieves 100% Remission Rate in Frontline AML Trial
Aptevo Therapeutics' mipletamig, combined with venetoclax and azacitidine, achieved a 100% remission rate within 30 days in Cohort 1 of the RAINIER trial for frontline AML.
ALG.APV-527 Bispecific Antibody Shows Promise in Phase 1 Solid Tumor Trial
Aptevo Therapeutics and Alligator Bioscience's ALG.APV-527 met key Phase 1 trial endpoints for safety, tolerability, and biological activity in solid tumors.